Ticker

Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company's Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today announced that it has initiated a potential sale or strategic partnership process for BE-Smart, its clinically validated…

UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings.

ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.12 and traded as low as $0.1740. ProPhase Labs shares last traded at $0.1998, with a volume of 490,748 shares traded. Analyst Upgrades and Downgrades Several equities

ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.26 and traded as low as $0.1661. ProPhase Labs shares last traded at $0.2799, with a volume of 1,509,825 shares changing hands. Analyst Ratings Changes Several research

UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company's underlying asset base.